Glucagon-like-peptide-1 (7-36) amide improves glucose sensitivity in beta-cells of NOD mice

Acta Diabetologica

Volumn 33, Issue 1, 1996, Pages 19-24

  Linn, T ^a   Schneider, K ^a   Goke B ^b   Federlin, K ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Glucagon like peptide 1; NOD mouse; Prediabetes

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULITIS; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS PERFUSION; PRIORITY JOURNAL;

ANIMALS; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; GLUCOSE; INSULIN; ISLETS OF LANGERHANS; KINETICS; MICE; MICE, INBRED NOD; MICE, MUTANT STRAINS; PANCREAS; PEPTIDE FRAGMENTS; TIME FACTORS;

EID: 0029968056     PISSN: 09405429     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00571935     Document Type: Article

References (24)

1. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeld W, Preserved incretin activity of glucagon-like-peptide 1 (7-36) amide, but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301-307, 1993
2. Ensinck JW, D'Allessio DA, The enteroinsular axis revisited. A novel role for an incretin. N Engl J Med 326:1352-1353, 1992
3. Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S, Antidiabetogenic effect of glucagon-like-peptide 1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316-1322, 1992
4. Hermann C, Göke R, Richter G, Fehmann HC, Arnold R, Göke B, GLP-1 and GIF plasma levels in response to nutrients. Digestion, in press, 1996
5. Eyll B van, Lankat-Butgereit B, Bode HP, Göke R, Göke B, Signal transduction of the GLP-1 receptor cloned from a human insulinoma. FEBS Lett 348:7-13, 1994
6. Lankat-Buttgereit B, Göke R, Stöckmann F, Fehmann HC, Göke B, Detection of the human GLP-1 receptor on insulinoma cell membranes. Digestion 55:29-33, 1994
7. Thorens B, Porret A, Bühler L, Deng SP, Morel P, Widman C, Cloning and functional expression of the human islet GLP-1 receptor: demonstration that exendin 4 is an agonist and exendin (9-39) an antagonist of the receptor. Diabetes 42:1678-1682, 1993
8. Goöke B (ed). International Symposium on Glucagon-like-peptide-1. Copenhagen. Denmark, May 17-19, Abstracts. Digestion 54:339-397, 1993
9. Strandell E, Sandier S, Boitard C, Eizirik DL, Role of infiltrating T-cells for impaired glucose metabolism in pancreatic islets isolated from non-obese diabetic mice. Diabetologia 35:924-931, 1992
10. Kano Y, Kanatsuna T, Nakamura N, Kitigawa Y, Mori H, Kajiyama S, Nakano K, Kondo M, Defect of the first phase insulin secretion to glucose stimulation in the perfused pancreas of the nonobese diabetic (NOD) mouse. Diabetes 35:486-490, 1986
11. Göke R, Fehmann HC, Göke B, Glucagon-like-peptide (7-36) amide is a new incretin enterogastrone candidate Eur J Clin Invest 21:135-144, 1991
12. Linn T, Loewk E, Schneider K, Federlin K, Spontaneous glucose intolerance in the progeny of low dose streptozotocin-induced diabetic mice. Diabetologia 36:1245-1251, 1993
13. Nagakawa S, Nakayama H, Sasaki T, Yoshino K, Yu YY, Shinozaki K, Aoki S, Mashimo K, A simple method for the determination of serum free insulin levels in insulin treated patients. Diabetes 22:590-600, 1973
14. Creutzfeldt W, Ebert R, New developments in the incretin concept. Diabetologia 28:565-573, 1985
15. Elahi D, McAloon-Dyke M, Fukagawa N, Meneilly GS, Sclater AL, Minaker KL, Habener JF, Anderson DK, The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept 51:63-74, 1994
16. Göke R, Wagner B, Fehmann HC, Göke B, Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7-36) amide on the rat pancreas. Res Exp Med 193:97-103, 1993
17. Kawai K, Suzuki S, Ohashi S, Mukai H, Ohmori H, Murayama Y, Yamashita K, Comparison of the effects of glucagon-like peptide-1-(7-37) and -(7-37) and glucagon on islet hormone release from isolated perfused canine and rat pancreases. Endocrinology 124:1768-1773, 1989
18. Hendrick GK, Gjinovci A, Baxter LA, Mojsov S, Wollheim CB, Habener JF, Weir GC, Glucagon-like-peptide-I-(7-37) suppresses hyperglycemia in rats. Metabolism 42:1-6, 1993
19. Weir GC, Mojsov S, Hendrick GK, Habener JF, Glucagonlike peptide I (7-37) actions on the endocrine pancreas. Diabetes 38:338-342, 1989
20. Boitard C, Bendelac A, Richard MF, Carnaud C, Bach JF, Prevention of diabetes in nonobese diabetic mice by anti-I-A monoclonal antibodies: transfer of protection by splenic T-cells. Proc Nat Acad Sci USA 85:9719-9723, 1988
21. Eizirik DL, Welsh M, Strandell E, Welsh N, Sandier S, Interleukin-1 depletes insulin messenger ribonucleic acid and increases the heat shock protein hsp 70 in mouse pancreatic islets without impairing the glucose metabolism. Endocrinology 127: 2290-2297, 1990
22. McDonald M, Elusive proximal signals of beta cells for insulin secretion. Diabetes 39:1461-1466, 1990
23. Fehmann HC, Göke R, Bächle R, Wagner B, Arnold R, Priming effect of glucagon-like-peptide-1 (7-37) amide, glucose-dependent insulinotropic peptide, and cholecystokinin-8 at the isolated perfused rat pancreas. Biochim Biophys Acta 1091:356-363, 1991
24. Holz GO, Kuhtreiber WM, Habener JF, Pancreatic beta cells are rendered glucose competent by the insulinotropic hormone glucagon-like-peptide-1 (7-37). Nature 361:362-365, 1993